Pharmacokinetics of PEG-rhG-CSF and rHSA-hG-CSF in mice determined with ELISA.
- Author:
Guo-chang MA
1
;
Shu-qing CHEN
;
Zhen-hong ZHU
;
Yan-shan HUANG
;
Hui-qiang PAN
;
Jin-bao ZHOU
Author Information
1. College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310031, China. mgc777@163.com
- Publication Type:Journal Article
- MeSH:
Animals;
Area Under Curve;
Enzyme-Linked Immunosorbent Assay;
methods;
Granulocyte Colony-Stimulating Factor;
blood;
chemistry;
pharmacokinetics;
Half-Life;
Humans;
Male;
Mice;
Mice, Inbred ICR;
Polyethylene Glycols;
chemistry;
Recombinant Fusion Proteins;
blood;
chemistry;
pharmacokinetics;
Recombinant Proteins;
Serum Albumin;
chemistry
- From:
Acta Pharmaceutica Sinica
2007;42(2):197-200
- CountryChina
- Language:Chinese
-
Abstract:
Double antibody sandwich-type ELISA was used to detect rhG-CSF in serum to study the pharmacokinetics of rhG-CSF, PEG-rhG-CSF and rHSA-hG-CSF in mice and to confirm that PEGlyation and albumin fusion of rhG-CSF technology can prolong half-life of G-CSF. Pharmacokinetic parameters were calculated with 3P87 software. T1/2 s of rhG-CSF, PEG-rhG-CSF and rHSA-hG-CSF are 2. 1 , 14.2 and 10. 6 h, respectively. T1/2 s of PEG- rhG-CSF and rHSA-hG-CSF are 7, 5 times than T1/2 s of rhG-CSF, respectively. Tpeak s of PEG-rhG-CSF and rHSA-hG-CSF are 15, 13 times than Tpeak of rhG-CSF, respectively. The result of ELISA indicates that PEGlyation and albumin fusion of rhG-CSF technology can prolong half-life of G-CSF.
